Cardiovascular Systems Inc Form SC 13G/A March 17, 2009

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

### **SCHEDULE 13G**

(Rule 13d-102)

Under the Securities Exchange Act of 1934

(Amendment No. 3)\*

# CARDIOVASCULAR SYSTEMS, INC. (f/k/a Replidyne, Inc.)

(Name of Issuer)

Common Stock, par value \$0.001 per share

(Title of Class of Securities)

14161906

(CUSIP Number)

February 25, 2009

(Date of Event which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

- O Rule 13d-1(d)
- o Rule 13d-1(d)
- Rule 13d-1(d)

X

The information required on the reminder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") orotherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

<sup>\*</sup>The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

CUSIP No.	14161906
SCHEDULE	13G

Page 2 of 19 Pages

NAME OF REPORTING PE		

#### Perseus-Soros BioPharmaceutical Fund, LP

2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

- (a) O
- (b) **x**

- 3 SEC USE ONLY
- 4 CITENZSHIP OR PLACE OF ORGANIZATION

#### Delaware

5	SOLE VOTING POWER
	148,780

NUMBER OF

SHARES 6

BENEFICIALLY SHARED VOTING POWER

OWNED BY

7

EACH SOLE DISPOSITIVE POWER

REPORTING 148,780

PERSON 8

SHARED DISPOSITIVE POWER

-0-

9 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

148,780

10 CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

o

PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

1.1%

12 TYPE OF REPORTING PERSON

PN

11

1.1%

1	NAME OF REPORTING PERSON S.S. O	R I.R.S.	INDENTIFICATION NO. OF ABOVE PERSO	N	
	Perseus-Soros Partners, LLC				
2	CHECK THE APPROPRIATE BOX IF A	МЕМВІ	ER OF A GROUP		O x
3	SEC USE ONLY				
4	CITENZSHIP OR PLACE OF ORGANIZA	ATION			
	Delaware				
		5	SOLE VOTING POWER 148,780		
SHA BEN OWI EAC	ORTING	6 7 8	SHARED VOTING POWER -0-  SOLE DISPOSITIVE POWER 148,780  SHARED DISPOSITIVE POWER -0-		
9	AGGREGATE AMOUNT BENEFICIALL	Y OWN	IED BY EACH REPORTING PERSON		
	148,780				
10	CHECK IF THE AGGREGATE AMOUNT	Γ IN RO	W (9) EXCLUDES CERTAIN SHARES		0

PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

11

1.1%

0 x

o

1	NAME OF REPORTING PERSON S.S. O	OR I.R.S	. INDENTIFICATION NO. OF ABOVE PERSON	1	
	Perseus BioTech Fund Partners, LLC				
2	CHECK THE APPROPRIATE BOX IF A	A MEMB	ER OF A GROUP	(a)	
3	SEC USE ONLY			(b)	
4	CITENZSHIP OR PLACE OF ORGANIZ	ZATION			
	Delaware				
		5	SOLE VOTING POWER		
SHA BEN OW! EAC	EFICIALLY NED BY 'H ORTING	6 7 8	SHARED VOTING POWER 148,780  SOLE DISPOSITIVE POWER -0- SHARED DISPOSITIVE POWER 148,780		
9	AGGREGATE AMOUNT BENEFICIAL  148,780	LY OW	NED BY EACH REPORTING PERSON		
10		NT IN RO	DW (9) EXCLUDES CERTAIN SHARES		(

PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

1	NAME OF REPORTING PERSON S.S. OF	R I.R.S.	INDENTIFICATION NO. OF ABOVE PERSON	I	
	SFM Participation, L.P.				
2	CHECK THE APPROPRIATE BOX IF A M	MEMBE	ER OF A GROUP	(a) (b)	
3	SEC USE ONLY				
4	CITENZSHIP OR PLACE OF ORGANIZA	ATION			
	Delaware				
SHA BEN OWN EAC	EFICIALLY NED BY H ORTING	<ul><li>5</li><li>6</li><li>7</li><li>8</li></ul>	SOLE VOTING POWER -0- SHARED VOTING POWER 148,780  SOLE DISPOSITIVE POWER -0- SHARED DISPOSITIVE POWER 148,780		
9	AGGREGATE AMOUNT BENEFICIALL  148,780	Y OWN	ED BY EACH REPORTING PERSON		
10	CHECK IF THE AGGREGATE AMOUNT	IN RO	W (9) EXCLUDES CERTAIN SHARES		o
11	PERCENT OF CLASS REPRESENTED B	Y AMO	UNT IN ROW (9)		

12 TYPE OF REPORTING PERSON

PN

1.1%

1	NAME OF REPORTING PERSON S.S. O	R I.R.S.	INDENTIFICATION NO. OF ABOVE PERSO	N	
	SFM AH LLC				
2	CHECK THE APPROPRIATE BOX IF A	MEMB)	ER OF A GROUP	(a) (b)	O <b>X</b>
3	SEC USE ONLY				
4	CITENZSHIP OR PLACE OF ORGANIZA	ATION			
	Delaware				
		5	SOLE VOTING POWER -0-		
SHA BEN	EFICIALLY	6	SHARED VOTING POWER 148,780		
EAC	ORTING	7	SOLE DISPOSITIVE POWER -0-		
PEK	SON	8	SHARED DISPOSITIVE POWER 148,780		
9	AGGREGATE AMOUNT BENEFICIALL	Y OWN	NED BY EACH REPORTING PERSON		
	148,780				
10	CHECK IF THE AGGREGATE AMOUNT	Γ IN RC	W (9) EXCLUDES CERTAIN SHARES		
					o
11	PERCENT OF CLASS REPRESENTED B	SY AMO	OUNT IN ROW (9)		

12 TYPE OF REPORTING PERSON

1	NAME OF REPORTING PERSON S.S. OF	R I.R.S.	INDENTIFICATION NO. OF ABOVE PERSON	N	
	Perseuspur, L.L.C.				
2	CHECK THE APPROPRIATE BOX IF A M	MEMBI	ER OF A GROUP	(a) (b)	O <b>X</b>
3	SEC USE ONLY				
4	CITENZSHIP OR PLACE OF ORGANIZA	TION			
	Delaware				
SHA BEN OWN EAC	EFICIALLY NED BY CH ORTING	<ul><li>5</li><li>6</li><li>7</li><li>8</li></ul>	SOLE VOTING POWER -0- SHARED VOTING POWER 148,780  SOLE DISPOSITIVE POWER -0- SHARED DISPOSITIVE POWER 148,780		
9	AGGREGATE AMOUNT BENEFICIALLY 148,780	Y OWN	IED BY EACH REPORTING PERSON		
10	CHECK IF THE AGGREGATE AMOUNT	`IN RO	W (9) EXCLUDES CERTAIN SHARES		0
11	PERCENT OF CLASS REPRESENTED BY	Y AMC	OUNT IN ROW (9)		

12 TYPE OF REPORTING PERSON\*

1.1%

1	NAME OF REPORTING PERSON S.S. O	R I.R.S.	INDENTIFICATION NO. OF ABOVE PERSON	1	
	Frank H. Pearl (in the capacity described	herein)			
2	CHECK THE APPROPRIATE BOX IF A	МЕМВІ	ER OF A GROUP	(a) (b)	
3	SEC USE ONLY				
4	CITENZSHIP OR PLACE OF ORGANIZA	ATION			
	United States				
NUM SHA	MBER OF RES	5	SOLE VOTING POWER -0- SHARED VOTING POWER		
OWN EAC	ORTING	7	148,780  SOLE DISPOSITIVE POWER -0-		
LEK	3011	8	SHARED DISPOSITIVE POWER 148,780		
9	AGGREGATE AMOUNT BENEFICIALL 148,780	Y OWN	ED BY EACH REPORTING PERSON		
10	CHECK IF THE AGGREGATE AMOUN	T IN RO	W (9) EXCLUDES CERTAIN SHARES		
					О
11	PERCENT OF CLASS REPRESENTED B	BY AMO	UNT IN ROW (9)		

IN

1	NAME OF REPORTING PERSON S.S. OF	R I.R.S.	INDENTIFICATION NO. OF ABOVE PERSON	I	
	George Soros (in the capacity described he	rein)			
2	CHECK THE APPROPRIATE BOX IF A M	MEMBE	ER OF A GROUP	(a) (b)	
3	SEC USE ONLY				
4	CITENZSHIP OR PLACE OF ORGANIZA United States	ATION			
	Office States				
SHA BEN OWN EAC	EFICIALLY NED BY H ORTING	<ul><li>5</li><li>6</li><li>7</li><li>8</li></ul>	SOLE VOTING POWER  -0-  SHARED VOTING POWER  148,780  SOLE DISPOSITIVE POWER  -0-  SHARED DISPOSITIVE POWER  148,780		
9	AGGREGATE AMOUNT BENEFICIALL  148,780	Y OWN	ED BY EACH REPORTING PERSON		
10	CHECK IF THE AGGREGATE AMOUNT	' IN RO	W (9) EXCLUDES CERTAIN SHARES		o
11	PERCENT OF CLASS REPRESENTED B	Y AMO	UNT IN ROW (9)		

IA

1.1%

1	NAME OF REPORTING PERSON S.S. O	R I.R.S.	INDENTIFICATION NO. OF ABOVE PERSO	N		
	Soros Fund Management LLC					
2	CHECK THE APPROPRIATE BOX IF A	MEMBI	ER OF A GROUP	(a) (b)	O <b>x</b>	
3	SEC USE ONLY					
4	CITENZSHIP OR PLACE OF ORGANIZA	ATION				
	Delaware					
SHA BEN OWN EAC	EFICIALLY NED BY CH ORTING	<ul><li>5</li><li>6</li><li>7</li><li>8</li></ul>	SOLE VOTING POWER -0- SHARED VOTING POWER 148,780  SOLE DISPOSITIVE POWER -0- SHARED DISPOSITIVE POWER 148,780			
9	AGGREGATE AMOUNT BENEFICIALL	Y OWN	IED BY EACH REPORTING PERSON			
	148,780					
10	CHECK IF THE AGGREGATE AMOUNT	Γ IN RO	W (9) EXCLUDES CERTAIN SHARES		o	
11	PERCENT OF CLASS REPRESENTED B	Y AMC	OUNT IN ROW (9)			

OO, IA

CUSIP No. 14161906 SCHEDULE 13G Page 11 of 19 Pages

#### Item 1. (a) Name of Issuer

Cardiovascular Systems, Inc. (f/k/a Replidyne, Inc.) (the "Company").

(b) Address of Issuer's Principal Executive Offices

651 Campus Drive

St. Paul, MN 55112

#### Item 2. (a) Names of Persons Filing

This Statement is being filed on behalf of each of the following persons (collectively, the "Reporting Persons")

- (i) Perseus-Soros BioPharmaceutical Fund, LP, a Delaware limited partnership ("Perseus-Soros");
- (ii) Perseus-Soros Partners, LLC, a Delaware limited liability company ("PSP GP" and general partner of Perseus-Soros);
- (iii) Perseus BioTech Fund Partners, LLC, a Delaware limited liability company ("PBFP Partners" and managing member of PSP GP);
- (iv) SFM Participation, L.P., a Delaware limited partnership ("SFM Participation" and managing member of PSP GP);
- (v) SFM AH LLC, a Delaware limited liability company ("SFM AH" and general partner of SFM Participation);
- (vi) Perseuspur, L.L.C., a Delaware limited liability company ("Perseuspur" and managing member of PBFP Partners);
- (vii) Mr. Frank H. Pearl ("Mr. Pearl" and managing member of Perseuspur);
- (viii) Mr. George Soros ("Mr. Soros" and Chairman of SFM LLC); and
- (ix) Soros Fund Management LLC, a Delaware limited liability company ("SFM LLC" and the sole managing member of SFM AH).

Page 12 of 19 Pages

#### (b) Address of Principal Business Office

The address of the principal business offices of (i) Perseus-Soros and (ii) PSP GP is 888 Seventh Avenue, 30th Floor, New York, NY 10106.

The address of the principal business offices of (i) PBFP Partners, (ii) Perseuspur and (iii) Mr. Pearl is 2099 Pennsylvania Ave., N.W., Suite 900, Washington, D.C. 20006.

The address of the principal business offices of (i) SFM Participation, (ii) SFM AH, (iii) SFM LLC and (iv) Mr. Soros is 888 Seventh Avenue, 33rd Floor, New York, NY 10106.

#### (c) <u>Citizenship</u>

- (i) Perseus-Soros a Delaware limited partnership
- (ii) PSP GP a Delaware limited liability company
- (iii) PBFP Partners a Delaware limited liability company
- (iv) SFM Participation a Delaware limited partnership
- (v) SFM AH a Delaware limited liability company
- (vi) Perseuspur a Delaware limited liability company
- (vii) Mr. Pearl United States
- (viii) Mr. Soros United States
- (ix) SFM LLC a Delaware limited liability company

#### (d) <u>Title of Class of Securities</u>

Common Stock, par value \$0.001 per share (the "Common Stock" or "Shares")

#### (e) <u>CUSIP Number</u>

14161906

Information contained herein concerning SFM Participation, SFM AH, SFM LLC and Mr. Soros has been provided by SFM LLC. Perseus-Soros, PSP GP, PBFP Partners, Perseuspur and Mr. Pearl assume no responsibility for such information. Information contained herein concerning PBFP Partners, Perseuspur and Mr. Pearl has been provided by each such Reporting Person. Perseus-Soros, PSP GP, SFM Participation, SFM AH, SFM LLC and Mr. Soros assume no responsibility for such information.

Page 13 of 19 Pages

Item 3. This statement is not being filed pursuant to either Rule 13d-1(b) or 13d-2(b) or (c).

#### **Item 4.** Ownership.

(a) Amount Beneficially Owned:

As of February 25, 2009, each of the Reporting Persons may be deemed to beneficially own 148,780 Shares.

(b) <u>Percentage Owned</u>:

Based on calculations made in accordance with Rule 13d-3(d), and there being 13,738,660 Shares outstanding as of March 10, 2009, each of the Reporting Persons may be deemed to beneficially own approximately 1.1% of the outstanding Common Stock, as of February 25, 2009.

- (c) Number of Shares as to Which Such Person Has:
  - (i) Each of Perseus-Soros and PSP GP may be deemed to have sole power to direct the voting and disposition of the 148,780 Shares beneficially owned by Perseus-Soros.
  - (ii) By virtue of the relationships between and among the Reporting Persons as described in Item 2, each of the Reporting Persons other than Perseus-Soros and PSP GP may be deemed to share the power to direct the voting and disposition of 148,780 Shares beneficially owned by Perseus-Soros.
- Item 5. Ownership of Five Percent or Less of a Class

If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities check the following box x.

Item 6. Ownership of More than Five Percent on Behalf of Another Person

Not applicable.

Item 7. <u>Identification and Classification of Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company</u>

Not applicable.

CUSIP No. 14161906 SCHEDULE 13G

Page 14 of 19 Pages

Item 8. Identification and Classification of Members of the Group

Not applicable. Notice of Dissolution of Group Item 9.

Not applicable. Certification

Item 10.

Not applicable.

[REMAINDER OF PAGE INTENTIONALLY LEFT BLANK]

Page 15 of 19 Pages

#### **SIGNATURES**

After reasonable inquiry and to the best of our knowledge and belief, the undersigned certify that the information set forth in this statement is true, complete and correct.

Dated March 17, 2009

#### PERSEUS-SOROS BIOPHARMACEUTICAL FUND, LP

By: Perseus-Soros Partners, LLC General Partner

By: SFM Participation, L.P. Managing Member

By: SFM AH LLC General Partner

By: Soros Fund Management LLC Managing Member

By: /s/ Jay Schoenfarber Name: Jay Schoenfarber

Title: Assistant General Counsel

Page 16 of 19 Pages

#### PERSEUS-SOROS PARTNERS, LLC

By: SFM Participation, L.P. Managing Member

By: SFM AH LLC General Partner

By: Soros Fund Management LLC Managing Member

By: /s/ Jay Schoenfarber Name: Jay Schoenfarber

Title: Assistant General Counsel

### PERSEUS BIOTECH FUND PARTNERS, LLC

By: Perseuspur, L.L.C. Managing Member

By: Frank H. Pearl Managing Member

By: /s/ Kenneth M. Socha Name: Kenneth M. Socha

Title: Attorney-in-Fact for Mr. Pearl

Page 17 of 19 Pages

#### SFM PARTICIPATION, L.P.

By: SFM AH LLC General Partner

By: Soros Fund Management LLC Managing Member

By: /s/ Jay Schoenfarber Name: Jay Schoenfarber

Title: Assistant General Counsel

### SFM AH LLC

By: Soros Fund Management LLC Managing Member

By: /s/ Jay Schoenfarber Name: Jay Schoenfarber

Title: Assistant General Counsel

# PERSEUSPUR, L.L.C.

By: Frank H. Pearl Managing Member

By: /s/ Kenneth M. Socha Name: Kenneth M. Socha

Title: Attorney-in-Fact for Mr. Pearl

Page 18 of 19 Pages

#### MR. FRANK H. PEARL

By: /s/ Kenneth M. Socha

Name: Kenneth M. Socha

Title: Attorney-in-Fact for Mr. Pearl

#### MR. GEORGE SOROS

By: /s/ Jay Schoenfarber

Name: Jay Schoenfarber

Title: Attorney-in-Fact for Mr. Soros

#### SOROS FUND MANAGEMENT LLC

By: /s/ Jay Schoenfarber

Name: Jay Schoenfarber

Title: Assistant General Counsel

CUSIP No. 14161906 SCHEDULE 13G Page 19 of 19 Pages

#### Exhibit Index

Exhibit 1. Joint Filing Agreement as required by Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, as

amended (previously filed).

Exhibit 2. Power of Attorney, dated June 16, 2005 appointing each of Armando T. Belly, Jodye Anzalotta,

Maryann Canfield, Jay Schoenfarber and Robert Soros as Attorney-In-Fact for George Soros

(previously filed).

Exhibit 3. Power of Attorney, dated December 6, 2007, appointing each of Kenneth M. Socha and Teresa Y.

Bernstein as Attorney-in-Fact for Frank H. Pearl (previously filed).